SCHEMBL1553328

SCHEMBL1553328

CCOC(=O)c1c(-c2cccc(Cl)c2)csc1N1C(=O)c2ccccc2C1=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.48
LMNA P02545 4/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
PRKCZ Q05513 1/20 0.47
MAPT P10636 3/20 0.45
MAPK1 P28482 1/20 0.45
ALOX5 P09917 4/20 0.45
PTGES O14684 1/20 0.45
HPGD P15428 4/20 0.44
KDM4E B2RXH2 2/20 0.44
CYP1A2 P05177 2/20 0.44
CYP2C9 P11712 2/20 0.44
CYP2C19 P33261 2/20 0.44
MEN1 O00255 1/20 0.44
GAA P10253 1/20 0.44
CYP2D6 P10635 1/20 0.44
KMT2A Q03164 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
TP53 P04637 2/20 0.44
HTT P42858 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1553963 0.89 ALDH1A1 (0.50) ALDH1A1LMNASMN1; SMN2MAPTMAPK1
SCHEMBL1554407 0.88 PRKCZ (0.61) ALDH1A1LMNASMN1; SMN2PRKCZMAPT
SCHEMBL1554259 0.88 ALDH1A1 (0.60) ALDH1A1LMNASMN1; SMN2PRKCZMAPT
SCHEMBL1554599 0.88 PRKCZ (0.47) ALDH1A1LMNASMN1; SMN2PRKCZMAPT
SCHEMBL1554495 0.87 PTPN1 (0.52) ALDH1A1LMNASMN1; SMN2PRKCZMAPT
SCHEMBL4252376 0.85 ALDH1A1 (0.53) ALDH1A1LMNASMN1; SMN2MAPTHPGD
SCHEMBL1553883 0.85 ALDH1A1 (0.55) ALDH1A1LMNASMN1; SMN2PRKCZMAPT
SCHEMBL1553396 0.84 HPGD (0.51) ALDH1A1LMNASMN1; SMN2PRKCZMAPT
SCHEMBL1554631 0.83 LMNA (0.42) ALDH1A1LMNAMEN1GAAKMT2A
SCHEMBL1554657 0.83 ALDH1A1 (0.49) ALDH1A1LMNASMN1; SMN2PRKCZMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1383463-B1 FUSED THIOPHENE COMPOUNDS AND USE THEREOF IN THE TREATMENT OF CHRONIC PAIN KING PHARMACEUTICALS INC (US) 2011-04-27 EP disclosed
EP-1383463-A4 PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE KING PHARMACEUTICALS INC (US) 2009-03-25 EP disclosed
US-7449490-B2 Pharmaceutically active compounds and methods of use KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) 2008-11-11 US disclosed
US-7101905-B2 Pharmaceutically active compounds and methods of use KING PHARMACEUTICALS RESEARCH & DEVELOPMENT, INC. (US) 2006-09-05 US disclosed
US-20060183921-A1 Pharmaceutically active compounds and methods of use KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. 2006-08-17 US disclosed
EP-1383463-A2 PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE King Pharmaceuticals, Inc. (US) 2004-01-28 EP disclosed
US-20030073733-A1 Pharmaceutically active compounds and methods of use KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. 2003-04-17 US disclosed
WO-2002083083-A2 PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE KING PHARMACEUTICALS, INC. (US) 2002-10-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060183921-A1 Pharmaceutically active compounds and methods of use TRPV1, TPMT, ACHE ALDH1A1 1591/4885LMNA 4578/4885SMN1; SMN2 72/4885
US-20030073733-A1 Pharmaceutically active compounds and methods of use TRPV1, TPMT, ACHE ALDH1A1 1591/4885LMNA 4578/4885SMN1; SMN2 72/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.